Inhibrx Biosciences, Inc. (INBX)
Largest Insider Buys in Sector
INBX Stock Price History Chart
INBX Stock Performance
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, …
Insider Activity of Inhibrx Biosciences, Inc.
Over the last 12 months, insiders at Inhibrx Biosciences, Inc. have bought $2.26M and sold $10.29M worth of Inhibrx Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Inhibrx Biosciences, Inc. have bought $14.53M and sold $6.72M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Kayyem Jon Faiz (director) — $1.52M. Lappe Mark (Chief Executive Officer) — $1.3M. Vuori Kristiina MD (director) — $199,997.
The last purchase of 18,750 shares for transaction amount of $266,102 was made by Kayyem Jon Faiz (director) on 2024‑11‑20.
List of Insider Buy and Sell Transactions, Inhibrx Biosciences, Inc.
| 2024-11-20 | director | 18,750 0.1292% | $14.19 | $266,102 | -0.43% | |||
| 2024-11-19 | director | 34,843 0.2402% | $14.23 | $495,708 | -0.21% | |||
| 2024-10-03 | director | 6,667 0.0451% | $15.00 | $100,005 | +5.98% | |||
| 2024-09-16 | Chief Executive Officer | 13,037 0.0885% | $17.13 | $223,324 | -9.90% | |||
| 2024-09-12 | Chief Executive Officer | 26,963 0.1859% | $15.05 | $405,793 | +4.58% | |||
| 2024-09-11 | director | 6,457 0.0443% | $15.07 | $97,307 | +0.07% | |||
| 2024-09-10 | Chief Executive Officer | 8,500 0.0588% | $15.19 | $129,115 | +3.69% | |||
| 2024-09-10 | director | 179 0.0012% | $15.00 | $2,685 | +3.69% | |||
| 2024-09-09 | Chief Executive Officer | 9,500 0.0657% | $15.21 | $144,495 | +3.32% | |||
| 2024-09-06 | Chief Executive Officer | 26,000 0.1824% | $15.29 | $397,540 | +4.05% | |||
| 2024-05-28 | Sale | Chief Scientific Officer | 300,000 0.5717% | $34.30 | $10.29M | -54.99% | ||
| 2023-08-28 | 10 percent owner | 511,627 1.13% | $19.35 | $9.9M | +32.30% | |||
| 2023-03-01 | Sale | Chief Scientific Officer | 40,000 0.1006% | $24.21 | $968,231 | -4.21% | ||
| 2023-02-28 | Sale | Chief Executive Officer | 60 0.0002% | $25.02 | $1,501 | -4.75% | ||
| 2023-02-02 | Sale | Chief Scientific Officer | 11,250 0.0285% | $25.45 | $286,355 | -8.76% | ||
| 2023-02-01 | Sale | Chief Scientific Officer | 28,750 0.0707% | $24.73 | $710,856 | -8.69% | ||
| 2023-01-24 | Sale | Chief Executive Officer | 4,335 0.0103% | $25.72 | $111,478 | -15.28% | ||
| 2023-01-23 | Sale | director | 9,500 0.0235% | $25.26 | $239,999 | -10.09% | ||
| 2023-01-23 | Sale | Chief Executive Officer | 21,665 0.0538% | $25.36 | $549,364 | -10.09% | ||
| 2023-01-04 | Sale | Chief Scientific Officer | 7,105 0.0171% | $23.48 | $166,829 | -6.31% |
Insider Historical Profitability
| Lappe Mark | Chief Executive Officer | 705548 4.8739% | $14.17 | 5 | 6 | |
| Kayyem Jon Faiz | director | 69843 0.4825% | $14.17 | 2 | 4 | |
| Vuori Kristiina MD | director | 20443 0.1412% | $14.17 | 3 | 0 | |
| Shabet Rose Sharon | director | 2427307 16.7679% | $14.17 | 1 | 0 | <0.0001% |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 511627 3.5343% | $14.17 | 4 | 0 | +25.6% |